Unitedhealthcare Community Plan of Arizona

Total Page:16

File Type:pdf, Size:1020Kb

Unitedhealthcare Community Plan of Arizona Clinical Pharmacy Program Guidelines for Antipsychotics- ARIZONA Program Prior Authorization Medication Antipsychotics Markets in Scope Arizona 1. Background: Preferred Typical Antipsychotics/ Non-Preferred Typical Antipsychotics Antimanic Agents Haldol® (haloperidol) concentrate/tablets* Triavil® (perphenazine-amitriptyline) tablet* Haldol decanoate® (haloperidol decanoate Moban (molindone) tablet solution)* Loxitane® (loxapine) capsules* Trilafon (perphenazine) tablets* Mellaril® (thioridazine) tablets* Navane® (thiothixene) capsules* Orap® (pimozide) tablets* Prolixin® (fluphenazine hydrochloride) concentrate/elixir/tablets* Prolixin® (fluphenazine decanoate) solution Stelazine® (trifluoperazine) tablets* Thorazine® (chlorpromazine) tablets /solution* Lithium carbonate capsules/tablets Lithium carbonate CR tablet (Lithobid)* Lithium solution Preferred Atypical Antipsychotics Non-Preferred Atypical Antipsychotics Abilify® (aripiprazole) tablets* Abilify Discmelt® (aripiprazole) orally Clozaril® (clozapine) tablets/orally disintegrating tablet dispersible tablet * Abilify MyCite (aripiprazole tablet with Geodon® (ziprasidone) capsules* sensor) Fazaclo (clozapine orally disintergrating Abilify Oral Solution® (aripiprazole) tablet) Caplyta (lumateperone) capsule Latuda (lurasidone) tablets Invega® (paliperidone) tablet Risperdal® (risperidone) oral solution/tablets* Fanapt® (iloperidone) tablets Risperdal M-Tab® (risperidone) orally Seroquel XR® (quetiapine extended release) disintegrating tablet* tablet Seroquel® (quetiapine) tablets* Perseris (risperidone) SubQ injection ® Zyprexa (olanzapine) tablets* Rexulti (brexpiprazole) tablet ® Zyprexa Zydis (olanzapine) orally Saphris (asenapine) sublingual tablet dispersible tablet* Secuado (asenapine) Symbyax (fluoxetine/ olanzapine) capsule Abilify Maintena ® (aripiprazole) IM Versacloz (clozapine) suspension injection Vraylar (cariprazine) capsule Aristada (aripiprazole lauroxil) IM injection Zyprexa Relprevv (olanzapine) IM injection Confidential and Proprietary, © 2020 UnitedHealthcare Services Inc. 1 Aristada (aripirazole lauroxil) Initio IM Injection Invega Sustenna ® (paliperidone) IM injection Invega Trinza ® (paliperidone) IM injection Risperdal Consta ® (risperidone) IM injection *Only generic versions are covered UHC C&S Plan Minimum Age Edits: Prior authorization is required for atypical antipsychotic claims for members less than the following ages: Generic Name Brand Name Age Edit PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral ARIPIPRAZOLE TABLETS ABILIFY health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral ASENAPINE MALEATE SUBLINGUAL SAPHRIS health provider PA Required for Ages < 18 years and patients ≥ 18 years when prescribed by a non-behavioral CLOZAPINE ORALLY DISPERSABLE TABLET FAZACLO health provider PA Required for Ages < 18 years and patients ≥ 18 years when prescribed by a non-behavioral CLOZAPINE TABLETS CLOZARIL health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral LURASIDONE HCL TABS LATUDA health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral OLANZAPINE ORALLY DISPERSABLE TABLET ZYPREXA ZYDIS health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral OLANZAPINE TABLETS ZYPREXA health provider PA Required for Ages < 6 years and patients ≥ 6 years when QUETIAPINE FUMARATE TABLETS SEROQUEL prescribed by a non-behavioral Confidential and Proprietary, © 2020 UnitedHealthcare Services Inc. 2 health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral RISPERIDONE ORALLY DISPERSABLE TABLET RISPERIDONE ODT health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral RISPERIDONE ORAL SOLUTION RISPERDAL health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral RISPERIDONE TABLETS RISPERDAL health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral ZIPRASIDONE HCL CAPSULES GEODON health provider PA Required for Ages < 18 years and patients 18 years and older when prescribed by a non- ARIPIPRAZOLE LAUROXIL ARISTADA and Aristada Initio Behavioral Health provider PA Required for Ages < 18 years and patients 18 years and older when prescribed by a non- ARIPIPRAZOLE SUSPENSION ABILIFY MAINTENA Behavioral Health provider PA Required for Ages < 18 years and patients 18 years and older when prescribed by a non- PALIPERIDONE PALMITATE SUSPENSION INVEGA SUSTENNA Behavioral Health provider PA Required for Ages < 18 years and patients 18 years and older when prescribed by a non- PALIPERIDONE PALMITATE SUSPENSION INVEGA TRINZA Behavioral Health provider PA Required for Ages < 18 years and patients 18 years and older when prescribed by a non- RISPERIDONE MICROSPHERES SUSPENSION RISPERDAL CONSTA Behavioral Health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral CHLORPROMAZINE HCL SOLUTION VARIOUS health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral CHLORPROMAZINE HCL TABLETS VARIOUS health provider Confidential and Proprietary, © 2020 UnitedHealthcare Services Inc. 3 PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral FLUPHENAZINE HCL CONCENTRATE VARIOUS health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral FLUPHENAZINE HCL ELIXIR VARIOUS health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral FLUPHENAZINE HCL TABLETS VARIOUS health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral HALOPERIDOL LACTATE CONCENTRATE VARIOUS health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral HALOPERIDOL TABLETS VARIOUS health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral LOXAPINE SUCCINATE CAPSULES LOXITANE health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral PERPHENAZINE TABLETS VARIOUS health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral PIMOZIDE ORAP health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral THIORIDAZINE HCL TABLETS VARIOUS health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral THIOTHIXENE CAPSULES VARIOUS health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral TRIFLUOPERAZINE HCL TABLETS VARIOUS health provider PA Required for Ages < 18 years FLUPHENAZINE DECANOATE SOLUTION FLUPHENAZINE DECANOATE and patients ≥ 18 years when Confidential and Proprietary, © 2020 UnitedHealthcare Services Inc. 4 prescribed by a non-behavioral health provider PA Required for Ages < 18 years and patients ≥ 18 years when prescribed by a non-behavioral HALOPERIDOL DECANOATE SOLUTION HALDOL DECANOATE health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral Lithium capsules/ tablets Lithium health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral Lithium CR tablets Lithobid health provider PA Required for Ages < 6 years and patients ≥ 6 years when prescribed by a non-behavioral Lithium solution Lithium health provider Off-labeled Use: Drug therapies must be utilized in accordance with FDA approved indications OR the uses found within the compendia of literature† AND the drug is being prescribed for a medically accepted indication that is recognized as a covered benefit by the applicable health plans’ program. Authorization for off-labeled use of medication will be evaluated on an individual basis. Review of an off-labeled request by the UnitedHealthcare Community & State Medical Staff will be predicated on the appropriateness of treatment, scientific evidence and full consideration of medical necessity. †-compendia of current literature: a. Food and Drug Administration (FDA) approved indications and limits, b. Published practice guidelines and treatment protocols, c. Comparative data evaluating the efficacy, type and frequency of side effects and potential drug interactions among alternative products as well as the risks, benefits and potential member outcomes, d. Drug Facts and Comparisons, e. American Hospital Formulary Service Drug Information, f. United States Pharmacopeia – Drug Information, g. DRUGDEX Information System, h. UpToDate, i. MicroMedex, j. Peer-reviewed medical literature, including randomized clinical trials, outcomes, research data and pharmacoeconomic studies, and k. Other drug reference resources Indications Confidential and Proprietary, © 2020 UnitedHealthcare Services Inc. 5 The intent of the criteria is to ensure the appropriate utilization of antipsychotic agents for the appropriate FDA labeled indications and consistent with current evidence in the literature. 2. Coverage Criteria: A. Preferred Antipsychotics: Antipsychotic Medications in Children Under 6 Years Old All of the following: 1. The patient has been diagnosed per current DSM criteria with one of the following disorders: a. Bipolar Spectrum Disorder
Recommended publications
  • Lumateperone Monograph
    Lumateperone (Caplyta®) Classification Atypical antipsychotic Pharmacology The mechanism of action of lumateperone tosylate (Caplyta, ITI-007) in the treatment of schizophrenia is unknown but it’s thought to simultaneously modulate serotonin, dopamine, and glutamate neurotransmission. Specifically, lumateperone acts as a potent 5-HT2A receptor antagonist, a D2 receptor presynaptic partial agonist and postsynaptic antagonist, a D1 receptor-dependent modulator of glutamate, and a serotonin reuptake inhibitor. Indication Treatment of schizophrenia in adults Boxed Warning Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Caplyta is not approved for the treatment of patients with dementia-related psychosis. Pharmacokinetics Pharmacokinetic Parameter Details Absorption Rapidly absorbed. Absolute bioavailability is about 4.4%. Cmax reached approximately 1 (fasting) to 2 h (food) post dosing. Ingestion of high fat meal lowers mean Cmax by 33% and increases mean AUC by 9% Distribution Protein binding = 97.4%. Volume of distribution (IV) = 4.1 L/kg Metabolism Extensively metabolized. T1/2 = 13-21 hours for lumateperone and metabolites Excretion Less than 1% excreted unchanged in urine 1 Texas Health and Human Services ● hhs.texas.gov Dosage/Administration 42 mg by mouth once daily with food. Dose titration is not required. Use in Special Population Pregnancy Neonates exposed to antipsychotic drugs during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Available data from Caplyta use in pregnant women are insufficient to establish any drug associated risks for birth defects, miscarriage, or adverse maternal or fetal outcomes. There are risks to the mother associated with untreated schizophrenia and with exposure to antipsychotics, including Caplyta, during pregnancy.
    [Show full text]
  • Papers and Originals
    BRITISH MEDICAL JOURNAL 19 FEBRUARY 1972 463 PAPERS AND ORIGINALS Drug Interaction: Inhibitory Effect of Neuroleptics on Metabolism of Tricyclic Antidepressants in Man LARS F. GRAM, KERSTIN FREDRICSON OVERO British Medical Journal, 1972, 1, 463-465 excretion (Anders, 1971). There are relatively few reports on interaction concerning neuroleptics or tricyclic antidepressants. Summary Chlorpromazine has both stimulatory and inhibitory effects on the metabolism of hexobarbitone in Total urinary excretion of radioactivity after oral or experimental animals of a test of (Riimke and Bout, 1960-1). Furthermore, chlorpromazine intravenous administration dose '4C-imi- accelerates the metabolism pramine was measured in were tested ofmeprobamate (Kato and Vassanelli, eight patients. They 1962). Tricyclic antidepressants have been shown to inhibit the before, during, and after treatment with neuroleptics. metabolism Excretion diminished while the were of tremorine and oxotremorine in rats in vitro and patients being in vivo (Hammer and Sjoqvist, 1967). It has also been found treated with perphenazine, haloperidol, or chlorproma- that zine, not treatment. desipramine hydrochloride inhibits the metabolism of though during flupenthixol amphetamine in isolated, perfused rat liver (Dingell and Bass, Total urinary excretion of radioactivity and plasma 1969). Pretreatment levels of metabolites and were measured with phenobarbitone decreased steady-state unchanged drug plasma levels of desipramine and nortriptyline in man (Sjoqvist in five patients after a test dose of 14C-nortriptyline. Each et was before and al. 1968). These findings were later confirmed in a twin study patient tested again during perphenazine (Alexanderson et al., 1969). Forrest et treatment. In all patients perphenazine treatment caused: al. (1970) found increased (1) decrease of total urinary excretion, (2) decreased urinary excretion of chlorpromazine metabolites when patients plasma level of metabolites, and (3) increased plasma were given additional treatment with phenobarbitone.
    [Show full text]
  • Atypical Antipsychotics TCO 02.2018
    Therapeutic Class Overview Atypical Antipsychotics INTRODUCTION • Antipsychotic medications have been used for over 50 years to treat schizophrenia and a variety of other psychiatric disorders (Miyamato et al 2005). • Antipsychotic medications generally exert their effect in part by blocking dopamine (D)-2 receptors (Jibson et al 2017). • Antipsychotics are divided into 2 distinct classes based on their affinity for D2 and other neuroreceptors: typical antipsychotics, also called first-generation antipsychotics (FGAs), and atypical antipsychotics, also called second- generation antipsychotics (SGAs) (Miyamato et al 2005). • Atypical antipsychotics do not have a uniform pharmacology or mechanism of action; these differences likely account for the different safety and tolerability profiles of these agents (Clinical Pharmacology 2020, Jibson et al 2017). The atypical antipsychotics differ from the early antipsychotics in that they have affinity for the serotonin 5-HT2 receptor in addition to D2. Clozapine is an antagonist at all dopamine receptors (D1-5), with lower affinity for D1 and D2 receptors and high affinity for D4 receptors. Aripiprazole and brexpiprazole act as partial agonists at the D2 receptor, functioning as an ○ agonist when synaptic dopamine levels are low and as an antagonist when they are high. Cariprazine is a partial agonist at D2 and D3. Pimavanserin does not have dopamine blocking activity and is primarily an inverse agonist at 5-HT2A receptors. The remaining atypical antipsychotics share the similarity of D2 and 5-HT2A
    [Show full text]
  • Schizophrenia Care Guide
    August 2015 CCHCS/DHCS Care Guide: Schizophrenia SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT GOALS ALERTS Minimize frequency and severity of psychotic episodes Suicidal ideation or gestures Encourage medication adherence Abnormal movements Manage medication side effects Delusions Monitor as clinically appropriate Neuroleptic Malignant Syndrome Danger to self or others DIAGNOSTIC CRITERIA/EVALUATION (PER DSM V) 1. Rule out delirium or other medical illnesses mimicking schizophrenia (see page 5), medications or drugs of abuse causing psychosis (see page 6), other mental illness causes of psychosis, e.g., Bipolar Mania or Depression, Major Depression, PTSD, borderline personality disorder (see page 4). Ideas in patients (even odd ideas) that we disagree with can be learned and are therefore not necessarily signs of schizophrenia. Schizophrenia is a world-wide phenomenon that can occur in cultures with widely differing ideas. 2. Diagnosis is made based on the following: (Criteria A and B must be met) A. Two of the following symptoms/signs must be present over much of at least one month (unless treated), with a significant impact on social or occupational functioning, over at least a 6-month period of time: Delusions, Hallucinations, Disorganized Speech, Negative symptoms (social withdrawal, poverty of thought, etc.), severely disorganized or catatonic behavior. B. At least one of the symptoms/signs should be Delusions, Hallucinations, or Disorganized Speech. TREATMENT OPTIONS MEDICATIONS Informed consent for psychotropic
    [Show full text]
  • Management of Side Effects of Antipsychotics
    Management of side effects of antipsychotics Oliver Freudenreich, MD, FACLP Co-Director, MGH Schizophrenia Program www.mghcme.org Disclosures I have the following relevant financial relationship with a commercial interest to disclose (recipient SELF; content SCHIZOPHRENIA): • Alkermes – Consultant honoraria (Advisory Board) • Avanir – Research grant (to institution) • Janssen – Research grant (to institution), consultant honoraria (Advisory Board) • Neurocrine – Consultant honoraria (Advisory Board) • Novartis – Consultant honoraria • Otsuka – Research grant (to institution) • Roche – Consultant honoraria • Saladax – Research grant (to institution) • Elsevier – Honoraria (medical editing) • Global Medical Education – Honoraria (CME speaker and content developer) • Medscape – Honoraria (CME speaker) • Wolters-Kluwer – Royalties (content developer) • UpToDate – Royalties, honoraria (content developer and editor) • American Psychiatric Association – Consultant honoraria (SMI Adviser) www.mghcme.org Outline • Antipsychotic side effect summary • Critical side effect management – NMS – Cardiac side effects – Gastrointestinal side effects – Clozapine black box warnings • Routine side effect management – Metabolic side effects – Motor side effects – Prolactin elevation • The man-in-the-arena algorithm www.mghcme.org Receptor profile and side effects • Alpha-1 – Hypotension: slow titration • Dopamine-2 – Dystonia: prophylactic anticholinergic – Akathisia, parkinsonism, tardive dyskinesia – Hyperprolactinemia • Histamine-1 – Sedation – Weight gain
    [Show full text]
  • Opipramol and Trifluoperazine in the Treatment of Anxiety and Tension
    A COMPARATIVE STUDY OF TWO ANTIHISTAMINES 395 In table VI are given the results of a question directed at discovering how effective the preferred treatment was compared to any other antihistamine used. Fifteen patients only were able to give this information but the results are interesting. Discussion TABLE VI The design of this study was very simple as COMPARISON WITH PREVIOUSLY USED ANTIHISTAMINE such studies must be if they are to be completed under the conditions of a busy general practice. In a condition such as hay fever where anti- Worse As good Better Total histamines are known to be etfective and where fairly rapid symptomatic relief is needed by the 2 4 9 15* patient, we did not feel justified in including a placebo. The results of the study seem fairly *In the majority of patients the previously used clear-cut that if patients are offered the choice antihistamine was the chemically related chlor- of a plain form of this antihistamine or a long- pheniramine maleate B.P. acting form more will choose the latter. Ofthose that do so, however, only about a third find a single tablet at night completely effective, the remainder have to take one further tablet during the day. Both forms of antihistamine are effective and where a retrospective comparison can be made this effectiveness is considered greater or equal to that of previously administered anti-histamines. Summary A simple comparative study under general-practice conditions of two formulations of pheniramine is described. Sixty-one per cent of patients preferred the long-acting form of this antihistamine.
    [Show full text]
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • Is Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment for Schizophrenia in Adult Patients? Kyle J
    Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Student Dissertations, Theses and Papers Scholarship 2017 Is Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients? Kyle J. Knowles Philadelphia College of Osteopathic Medicine Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews Part of the Psychiatry Commons Recommended Citation Knowles, Kyle J., "Is Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients?" (2017). PCOM Physician Assistant Studies Student Scholarship. 381. https://digitalcommons.pcom.edu/pa_systematic_reviews/381 This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu. Is Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients? Kyle J. Knowles, PA-S A SELECTIVE EVIDENCE BASED MEDICINE REVIEW In Partial Fulfillment of the Requirements For The Degree of Master of Science In Health Sciences- Physician Assistant Department of Physician Assistant Studies Philadelphia College of Osteopathic Medicine Philadelphia, Pennsylvania December 16, 2016 ABSTRACT OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is Aristada (aripiprazole lauroxil) a safe and effective treatment for schizophrenia in adult patients?” STUDY DESIGN: Review of three randomized controlled studies. All three trials were conducted between 2014 and 2015. DATA SOURCES: One randomized, controlled trial and two randomized, controlled, double- blind trials found via Cochrane Library and PubMed.
    [Show full text]
  • PERPHENAZINE and AMITRIPTYLINE HYDROCHLORIDE- Perphenazine and Amitriptyline Hydrochloride Tablet, Film Coated Mylan Pharmaceuticals Inc
    PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE- perphenazine and amitriptyline hydrochloride tablet, film coated Mylan Pharmaceuticals Inc. ---------- WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug- treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Perphenazine and amitriptyline hydrochloride is not approved for the treatment of patients with dementia- related psychosis (see WARNINGS). Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of perphenazine and amitriptyline or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need.
    [Show full text]
  • Lumateperone for Acute Exacerbations of Psychosis in Schizophrenia NIHRIO (HSRIC) ID: 10603 NICE ID: 9131
    NIHR Innovation Observatory Evidence Briefing: May 2017 Lumateperone for acute exacerbations of psychosis in schizophrenia NIHRIO (HSRIC) ID: 10603 NICE ID: 9131 LAY SUMMARY Schizophrenia is a chronic mental health disorder causing changes in people’s thoughts and behaviour. Common symptoms include hallucinations (experiencing things that aren’t there), delusions (strong and unusual beliefs), confusion and disorganised thoughts. Schizophrenic symptoms usually come and go in ‘episodes’, where for a period of time symptoms may become more severe. Schizophrenia is usually treated with different types of psychological therapies and antipsychotic drugs which alter the levels of chemicals such as dopamine and serotonin in the brain. However, antipsychotic drugs can cause side effects including drowsiness, weight gain, blurred vision, constipation, lack of libido and dry mouth. Lumateperone is a new, orally administered antipsychotic drug which alters levels of several chemicals in the brain including dopamine, serotonin and glutamate. Studies on lumateperone in people with schizophrenia experiencing an episode of severe symptoms suggest it may reduce symptoms with less side effects than current antipsychotic medication. If licensed lumateperone may provide an alternative treatment option for people with schizophrenia which may cause fewer side effects. This briefing is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or commissioning without additional information. This briefing presents independent research funded by the National Institute for Health Research (NIHR). The views expressed1 are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health.
    [Show full text]
  • Clinical Guideline Drug/Drug Class: Antipsychotics Prepared By
    MassHealth Drug Utilization Review Program Commonwealth Medicine University of Massachusetts Medical School P.O. Box 2586 Worcester MA, 01613-2586 Clinical Guideline Drug/Drug Class: Antipsychotics Prepared by: Drug Utilization Review Program Prepared for: MassHealth Pharmacy Program Purpose: The purpose of this guideline is to clarify the procedures for approving and denying prior authorization (PA) requests for: Polypharmacy with two or more antipsychotics for members ≥ 18 years old (including first- generation [typical] and second-generation [atypical]) for greater than 60 days (excluding clozapine and injectable formulations) Orally disintegrating dosage forms and Versacloz® (clozapine) oral suspension Medication exceeding defined quantity limits Fanapt® (iloperidone), Invega® (paliperidone), Latuda® (lurasidone), Rexulti® (brexpiprazole), Saphris® (asenapine), and Vraylar® (cariprazine) for members of all ages and all quantities Abilify® (aripiprazole) and Seroquel XR® (quetiapine extended-release) for members 18 years of age and older and all quantities Background: Since 2003, MassHealth has determined that oral second-generation (atypical) antipsychotics (with the exception of clozapine and injectables) would require prior authorization for polypharmacy, defined as two or more second-generation (atypical) antipsychotics for greater than 60 days. Clozapine is excluded from the polypharmacy requirement because the guidelines for the treatment of schizophrenia recognize that combinations including clozapine have been reported. 1 In 2016, the adult antipsychotic polypharmacy criteria was updated and the PA restriction was expanded to include first-generation (typical), and second-generation (atypical) antipsychotics, excluding clozapine and injectable formulations. Orally disintegrating tablets (ODT) of aripiprazole, clozapine, olanzapine and risperidone, as well as Versacloz® (clozapine) oral suspension also require PA since there are more cost-effective alternatives available.
    [Show full text]
  • Heat Related Illness in Psychotropic Medication Users
    Common psychotropic medications which Prevention of Heat can impair your response to heat Related Illness Trade Name Generic Name Abilify aripiprazole During periods of high temperature (85º Asendin amoxapine and above) and humidity, there are things Artane trihexyphenidyl everyone, particularly people at high risk, Aventil, Pamelor nortriptyline should do to lessen the chances of heat Clozaril clozapine illness. Cogentin benztropine Compazine prochlorperazine ¾ Try to stay cool. Desyrel trazodone • Stay in air conditioned areas if Elavil, Limbitrol, possible. If you do not have air Triavil amitriptyline conditioning at home, go to a Eskalith, Lithobid, shopping mall or public library. Lithonate lithium • Keep windows shut and draperies, Geodon ziprasidone shades, or blinds drawn during the Haldol haloperidol heat of the day. Loxitane loxapine • Open windows in the evening or Ludiomil maprotiline night hours when the air outside is Mellaril thioridazine Heat Related Illness cooler. Moban molindone • Move to cooler rooms during the Navane thiothixene in heat of the day. Norpramin desipramine Psychotropic ¾ Avoid overexertion and outdoor Phenergan promethazine activity, particularly during warmer Prolixin fluphenazine Medication Users periods of the day. Risperdal risperidone ¾ Apply sunscreen and lotion as needed. Serentil mesoridazine Seroquel quetiapine ¾ Drink plenty of fluids (avoid coffee, tea, and alcohol). Sinequan doxepin ¾ Dress in loose fitting, light colored Stelazine trifluoperazine clothing. Wear a hat, sunglasses, and Thorazine chlorpromazine other protective clothing. Tofranil imipramine ¾ Take a cool shower or bath. Trilafon perphenazine ¾ Lose weight if you are overweight. Wellbutrin buproprion ¾ Eat regular meals to ensure that you Zyprexa olanzapine Ohio Department of Mental Health have adequate salt and fluids. *Note: This is not an all inclusive list.
    [Show full text]